March 27,2019
Grassley, Wyden Seek Info on Pharma Kickbacks to Patient Assistance Programs
WASHINGTON
– Senate Finance Committee Chairman Chuck Grassley of Iowa and Ranking Member
Ron Wyden of Oregon are seeking information from the Department of Health and
Human Services (HHS) Office of Inspector General (OIG) regarding recent federal
investigations into potential illegal kickback schemes by some pharmaceutical
companies to exploit charitable organizations by giving them money to pay the
copays of Medicare patients while encouraging the use of the companies’ own
drugs.
The
charitable organizations, known as patient assistance programs (PAPs), are
meant to help lower-income patients receive prescription drugs. The PAPs
receive financial donations from pharmaceutical companies and are sometimes
independent or associated with drug manufacturers. The Department of Justice
has recently settled with multiple pharmaceutical companies under the False
Claims Act for engaging in potentially illegal kickback schemes.
“The
Anti-Kickback Statute prohibits companies from offering or paying, directly or
indirectly, any remuneration to induce Medicare patients to purchase products,”
the senators wrote. “Improper coordination and kickbacks are serious problems
that undercut the integrity of the patient assistance process.” The leaders of
the Senate Finance Committee are asking the HHS OIG for a list of patient
assistance programs for which it has issued and/or withdrawn legal opinions and
copies of those opinions.
Last
month, Grassley and Wyden launched
a bipartisan investigation into the rising price of insulin which included
asking leading manufacturers to provide a list of all patient assistance
programs the companies have used or funded. The Finance Committee has
jurisdiction over the Medicare and Medicaid programs. It also has
jurisdiction over the laws and regulations governing tax exempt organizations.
The
letter can be found here
or below.
The
Honorable Daniel R. Levinson
Inspector
General
U.S.
Department of Health & Human Services
330
Independence Ave. SW
Washington,
DC 20201
Dear
Inspector General Levinson,
According to news reports, on November 28,
2017, your office rescinded an advisory opinion for a charitable organization
regarding its activities related to the Caring Voice Coalition (CVC), a patient
assistance program (PAP).[1] Shortly
thereafter, on December 20, 2017, the Justice Department issued a press release
announcing that United Therapeutics agreed to pay $210 million to resolve False
Claims Act liability for paying kickbacks.[2]
The settlement agreement mentioned that United Therapeutics used the Caring
Voice Coalition as a conduit to pay the copay obligations of thousands of
Medicare patients that used their drugs. Since
the rescission and the United Therapeutics settlement were announced, Actelion
Pharmaceuticals, Pfizer, Jazz Pharmaceuticals, and Lundbeck have each
reached multi-million dollar settlements related to improper coordination with
PAPs.[3]
The Anti-Kickback Statute prohibits
companies from offering or paying, directly or indirectly, any remuneration to
induce Medicare patients to purchase products. Improper coordination and
kickbacks are serious problems that undercut the integrity of the patient
assistance process. To better understand the scope and nature of this issue, we
are requesting that your office provide us with the following, no later than
April 3, 2019:
1.
A
list of those entities for which the Office of Inspector General has issued
favorable advisory opinions for their patient assistance activities. Please
include the current status of each advisory.
2.
Unredacted
copies of all advisory opinions currently in effect.
3.
Unredacted
copies of all notices of rescission that have been issued.
Thank you for your attention to this
important matter. If you or your staff have any questions, please contact Josh
Flynn-Brown of Chairman Grassley’s staff or Peter Gartrell of Ranking Member
Wyden’s staff at (202) 224-4515.
Sincerely,
Charles E.
Grassley
Ron Wyden
Chairman
Ranking Member
Committee on
Finance
Committee on Finance
[1] Ben Elgin and
Robert Langreth, Drug Charity May Shutter After U.S. Faults Pharma Influence,
Bloomberg (Nov. 29, 2017), https://www.bloomberg.com/news/articles/2017-11-29/pharma-charity-may-shut-after-u-s-faults-drugmakers-influence.
[2] See Press Release,
U.S. Dep’t. of Justice, Drug Maker United Therapeutics Agrees to Pay $210
Million to Resolve False Claims Act Liability for Paying Kickbacks (Dec.
20, 2017), https://www.justice.gov/opa/pr/drug-maker-united-therapeutics-agrees-pay-210-million-resolve-false-claims-act-liability.
[3] Nate Raymond, J&J
Unit to Pay $360 Million to U.S. to Resolve Charity Kickback Probe, Reuters (Dec. 6, 2018), https://www.reuters.com/article/us-johnson-johnson-settlement/jj-unit-to-pay-360-million-to-u-s-to-resolve-charity-kickback-probe-idUSKBN1O51XB.
Next Article Previous Article